Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Millán Prada, Henry Augusto"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Millán Prada, Henry Augusto
Publikováno v:
Laupland KB. Incidence of bloodstream infection: a review of population-based studies. Clin Microbiol Infect 2013;19(6):492-500
Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG, Hellmich M, Hopkins S, et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014;68(3):242–51
Moise PA, Schentag JJ: Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents. 2000;16 Suppl 1:S31-4
Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact: J. Infect. Dis. 2005;191(12):2149-52
Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, doubleblind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;15(6):641–50
Mariani PG, Sader HS, Jones RN: Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 2006;58(2):481–83
Zhong NS, Sun T, D’Souza G, Lee SH, Lan NH, Chiang CH, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with communityacquired pneumonia: a randomised, controlled, double-blind, phase 3, noninferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161-71
J Horcajada et al. Ceftaroline, a new broad-spectrum cephalosporin in the era of multiresistance. Enferm Infecc Microbiol Clin. 2014;32(Supl 2):1-7.
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections. Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42(3):389-91
Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA. 2009;301(7):727-36
Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillinresistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5(5):275-86
Vandenesch F, Naimi T, Enright MC, et al. Community acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9(8):978-84.
Casadevall A. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection? Fungal Genetics and Biology. 2005;42(2):98–106.
Soliman MS, Soliman NS, El-Manakhly AR, ElBanna SA, Aziz RK, El-Kholy AA. Genomic characterization of methicillin-resistant Staphylococcus aureus (MRSA) by high-throughput sequencing in a tertiary care hospital. Genes (Basel). 2020;11(10):1219
Bassetti M, Russo A, Cilloniz C, Giacobbe DR, Vena A, Amaro R, et al. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020;55(4):105921.
Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D, et al. Off-label use of ceftaroline fosamil: A systematic review. Int J Antimicrob Agents. 2019;54(5):562–71.
Hernández F. Cost-effectiveness of ceftolozane/ tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia. Infectio. 2020;24(1).
2011 Sesión extraordinaria presencial 15 de noviembre. Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA; Comisión revisora sala especializada de medicamentos y productos biológicos, Acta 53. 2011.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG, Hellmich M, Hopkins S, et al. Staphylococcus aureus bloodstream infection: a pooled analysis of five prospective, observational studies. J Infect. 2014;68(3):242–51
Moise PA, Schentag JJ: Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents. 2000;16 Suppl 1:S31-4
Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact: J. Infect. Dis. 2005;191(12):2149-52
Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, doubleblind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;15(6):641–50
Mariani PG, Sader HS, Jones RN: Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 2006;58(2):481–83
Zhong NS, Sun T, D’Souza G, Lee SH, Lan NH, Chiang CH, et al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with communityacquired pneumonia: a randomised, controlled, double-blind, phase 3, noninferiority with nested superiority trial. Lancet Infect Dis. 2015;15(2):161-71
J Horcajada et al. Ceftaroline, a new broad-spectrum cephalosporin in the era of multiresistance. Enferm Infecc Microbiol Clin. 2014;32(Supl 2):1-7.
Klevens RM, Edwards JR, Tenover FC, McDonald LC, Horan T, Gaynes R; National Nosocomial Infections. Surveillance System. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis. 2006;42(3):389-91
Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA. 2009;301(7):727-36
Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillinresistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis 2005;5(5):275-86
Vandenesch F, Naimi T, Enright MC, et al. Community acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 2003;9(8):978-84.
Casadevall A. Fungal virulence, vertebrate endothermy, and dinosaur extinction: is there a connection? Fungal Genetics and Biology. 2005;42(2):98–106.
Soliman MS, Soliman NS, El-Manakhly AR, ElBanna SA, Aziz RK, El-Kholy AA. Genomic characterization of methicillin-resistant Staphylococcus aureus (MRSA) by high-throughput sequencing in a tertiary care hospital. Genes (Basel). 2020;11(10):1219
Bassetti M, Russo A, Cilloniz C, Giacobbe DR, Vena A, Amaro R, et al. Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. Int J Antimicrob Agents. 2020;55(4):105921.
Pani A, Colombo F, Agnelli F, Frantellizzi V, Baratta F, Pastori D, et al. Off-label use of ceftaroline fosamil: A systematic review. Int J Antimicrob Agents. 2019;54(5):562–71.
Hernández F. Cost-effectiveness of ceftolozane/ tazobactam for the treatment of complicated intraabdominal and urinary tract infections in Colombia. Infectio. 2020;24(1).
2011 Sesión extraordinaria presencial 15 de noviembre. Instituto Nacional de Vigilancia de Medicamentos y Alimentos – INVIMA; Comisión revisora sala especializada de medicamentos y productos biológicos, Acta 53. 2011.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Las infecciones por especies de Staphylococcus Resistente a la Meticilina (SAMR) son un problema importante en el contexto hospitalario y cada vez más frecuente en la comunidad. En la actualidad las alternativas para el manejo de dichas infecciones,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4e535fd29b17c6d10d47d7e15a21076
